攝護腺癌荷爾蒙治療與5α-還原酶抑制劑之使用分析
柳瑞明1, 莊恆彰1, 吳俊德2 許仁駿3
1衛生福利部桃園醫院 泌尿科;2長庚醫療財團法人基隆長庚紀念醫院 泌尿科; 3佛教慈濟醫療財團法人花蓮慈濟醫院 癌症研究中心
Association Between 5α-Reductase Inhibitors and Androgen Deprivation Therapy
Jui-Ming Liu1, Heng-Chang Chuang1, Chun-Te Wu2 Ren-Jun Hsu 3
1Division of Urology, Department of Surgery Taoyuan General Hospital, Ministry of Health and Welfare
2 Department of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan
3 Cancer Medicine Center of Buddhist Hualien Tzu Chi Hospital, Tzu Chi University, Hualien, Taiwan
Background:
Androgen deprivation therapy (ADT) is widely used in advanced prostate cancer. To test the impact of 5α-reductase inhibitors(5-ARIs) on ADT users.
Methods:
We used data from the National Health Insurance Research Database of Taiwan between 1997 and 2016. The study subjects were divided into 5-ARIs users and non-user controls. The demographic characteristics and comorbidities were used t test. Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of thyroid diseases.
Results:
There were 44,566 patients who received ADT. Of those patients, 3,332 patients were 5-ARIs users and 35,489 were non-users. Compared with non-users, 5-ARIs users showed no increased risk of all-cause mortality (hazard ratio [HR]: 0.96; 95% confidence interval [CI]: 0.89–1.04)
Conclusions:
The 5-ARIs were not increase risk of mortality in patients received ADT. Further studies are warranted to have fully investigation.